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Background: Obesity is an increasing health problem worldwide, and is associated with severe 
negative health consequences such as increased risk of different types of cancer, including 
colorectal cancer. Bariatric surgery (BS) is one of the most used therapies to treat morbid 
obesity. Along with the reduced weight comes several positive health consequences, including 
reduced risk of obesity related cancers. However, some preliminary data are showing an 
increased risk of colorectal cancer after BS. Different theories connected to the metabolically 
changes after BS are suggested to explain this.  
 
Aim and methods: This thesis was a part of a project where the aim was to evaluate the effect 
of weight loss on the gut environment. The overall aim of this thesis was to evaluate changes 
in faecal water (FW) cytotoxicity, diet and stool consistency in patients after BS. Three groups 
of patients were recruited to a 1-year follow-up study including 5 study visits. One group 
underwent Roux-en-Y-gastric-bypass (RYGB), the second group underwent sleeve 
gastrectomy (SG), and the third group were obese, but otherwise healthy individuals serving as 
controls. FW cytotoxicity was determined by use of Water-soluble tetrazolium salt-1 assay. 
Energy and macronutrient intake were registered for one week before visits by the patients 
using MyFitnessPal.  
 
Results: Nine participants were included in the cytotoxicity analysis (5 BS and 4 control). 
Cytotoxicity as measured by the inhibitory concentration-50 levels were observed to be higher 
among the BS patients compared to the participants in the control group. In total sixty-seven 
participants (30 RYGB, 20 SG, 17 control) were included in the energy and macronutrient 
analysis. Energy, carbohydrate and fat intake were decreased in all three groups at 12 months 
compared with baseline. Protein intake in contrast, was increased between baseline and 12 
months for the SG group, and decreased in the two remaining groups.  
 
Conclusion: In conclusion, a trend of higher cytotoxicity levels was seen in BS patients 
compared to healthy, obese controls. The cytotoxicity gradually increased between 2 weeks and 
12 months after surgery in the BS group. The energy and macronutrient analysis showed a 
difference in the overall energy, fat and carbohydrate intake between both RYGB and control, 
and SG and control. 
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1.1 Overweight and obesity 
The increasing prevalence of obesity among both adults and children has become an widespread 
health problem worldwide (1). Since 1975, the prevalence of obesity has nearly tripled, and in 
2016 over 650 million adults were obese (2). The World Health Organization (WHO) defines 
overweight as a body mass index (BMI) of 25 or higher, while obesity is defined as a BMI 
equal to or higher than 30 (2). Excessive fat accumulation is associated with serious health 
consequences, increased risk of colorectal cancer (CRC) being one of them (3). Of note, 
overweight and obesity is largely preventable, and to some degree reversible by different types 
of therapy. The go-to strategy of weight loss in Europe is the multicomponent lifestyle 
intervention (4). This includes the simultaneously implementation of behavioural training, 
dietary change to reduce the energy intake, and an increase in physical activity. For patients 
who fail to achieve, and sustain weight loss from the latter approach, there can be indications 
for adding pharmacotherapy (4).  
 
1.2 Bariatric surgery 
Bariatric surgery (BS) is one of the most common methods to induce weight reduction in 
morbidly obese patients, and is associated with durable and effective weight loss. (5-7). Patients 
with morbid obesity (BMI40.0 kg/m2), or with comorbidities and with BMI35 kg/m2 are 
candidates for BS (8). In 2013, 468.609 BS were performed worldwide where Roux-en-Y-
Gastric-Bypass (RYGB) was applied in the majority of these cases, followed by Sleeve 
Gastrectomy (SG) (9). Weight loss after BS is associated with lower mortality rates, and a 
reduced prevalence of multiple lifestyle-related diseases (10, 11). The latter was shown in a 
large study that examined whether lower mortality was associated with weight loss induced by 
BS in Swedish obese individuals (The Swedish Obese subjects study (SOS)) (11). The study 
involved 4047 obese subjects: 2010 underwent BS, and 2037 received conventional treatment.  
 
1.2.1 Bariatric procedures  
Two of the most commonly used bariatric procedures, are RYGB and SG (9). In RYGB a large 
part of the stomach is removed from nutrient contact, creating a small stomach pouch of 
approximately 30ml. The distal part of the jejunum is connected to this pouch, where the length 
of this can vary. In contrast to RYGB, there are no anatomical rearrangements of the intestines 
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when performing a SG. In this procedure, approximately 70% of the stomach is permanently 





Figure 1A: Vertical sleeve gastrectomy (5).      Figure 1B: Roux-en-Y-gastric-bypass (5). 
 
RYGB and SG are combined restrictive and malabsorptive procedures (5). These procedures 
are restrictive in the way that the calorie intake must be adapted to the reduction of the stomach. 
Malabsorption comes from a reduced absorption area, decreased gastrointestinal (GI) secretions 
and diversion of nutrients from the duodenum (12). The duodenum is not effected in SG and is 
because of this regarded as less malabsorptive compared to RYGB. SG is also categorized as 
only restrictive by some (12). 
 
1.2.2 Metabolic effects after bariatric surgery  
BS is often called metabolic surgery, because of the multiple beneficial effects on the general 
metabolic state (13). This is thought to arise from changes in pancreatic hormones, gut 
hormones, bile acids (BAs) metabolism and the gut microbiome (7). For a long period, weight 
loss was considered as a sole reason for the beneficial health effects post BS. However, the 
positive health effects arising from BS can only be partly explained as a result of the induced 
weight loss (14). It is of note interesting that a large part of the post-operative metabolic changes 
take place before weight loss occurs (13). However, weight loss itself is also a contributor of 
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metabolically changes, as for example changes in peptide hormone secretion (15). The fact that 
both BS itself, and the weight loss that follows can cause metabolic changes makes it difficult 
to detect the cause of effect. 
 
Some of the positive metabolic effects occurring after BS are including an increase in several 
peptide gut hormones involved in promoting satiety (13). The pancreatic peptide hormone 
insulin is suggested to be involved in the early positive metabolic effects post BS (16). Insulin 
sensitivity seems to improve after RYGB, and fasting insulin levels are found to decrease short 
time after both SG and RYGB. Improved beta cell function is proposed as a part of the 
explanation for the ability of BS in type 2 diabetes remission (16-18).  
 
Altered BA metabolism and intestinal microbiota composition has frequently been suggested 
as contributors to the not-weight loss related metabolically effects after BS (19, 20). The results 
in studies looking at changes in BAs in association with BS are different in terms of the different 
BS procedures (5) (21). Research has shown to be more consistent in finding when it comes to 
changes in BAs after RYGB compared to other procedures (5). Most studies have concluded 
with increased fasting or postprandial total BA concentrations following RYGB (5, 22, 23). For 
SG, the results are more conflicting with some studies showing an increase of total BA 
concentration post-surgery compared with baseline (19, 24), while others are showing no 
increase (21, 25).  
 
The gut microbiota are shown to change after BS (26, 27). The gastric restriction or 
rearrangement of the intestinal tract during a RYGB or SG can lead to changes in the intestinal 
microorganism pattern (28). This could be the result of reduced gastric acid production, causing 
an increased pH level in the colon. An incompletely digested diet as a result of the 
rearrangement of the intestinal tract, in addition to the change in digestive enzymes, could also 
possibly alter the gut environment, and effect the composition of the intestinal bacteria (28). 
Among other functions, microbiota plays a key role in modulating BAs. In the colon, primary 
BAs are deconjugated and further transformed into secondary Bas by bacteria (28).  
 
1.2.3 Side effects and negative effects of bariatric surgery 
Even though BS reduces overall mortality and morbidity, several negative consequences can 
occur after surgery. A Danish survey conducted in 2238 RYGB patients, examined surgical, 
medical and nutritional symptoms after BS, and the association with quality of life. 88.6% of  
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the patients reported one or more symptoms short term after surgery, where nearly one third 
was at some point hospitalized. The most frequently reported complaints were fatigue (54.3%), 
dumping (52.4%), and abdominal pain (54.4%) However, most patients reported improved 
wellbeing (29).  
 
GI problems seems to be among the most frequently reported short-term side effects after 
different BS procedures (30). Constipation and diarrhoea are some of the most commonly GI 
problems reported (31). It is often difficult to determine if the complications can be directly 
related to the surgery, or to the change of diet that is associated with BS. Especially the liquid 
restrictions can off note have an effect on the constipation. It is difficult to counteract 
constipation when patients are only allowed to drink limited amounts, in addition to the 
possibility of being hindered because of discomfort, due to their restricted GI system. 
 
 
1.2.4 Bariatric surgery and food intake  
BS is an option for those where lifestyle- and medication-based approaches have been proven 
ineffective (32). To lose weight after BS and maintain weight loss its crucial to continuously 
restrict the energy intake. After BS, patients are asked to follow a staged progression diet 
starting with only liquids, and thereafter slowly adapt to solid food intake again (33). At 3 
months post-surgery, patients are encouraged obtain a normal diet so that they can adapt to their 
new GI system. It is crucial for the patients to consume small and frequent, rather than bigger 
meals, to adjust to their new GI system, and avoid discomfort (33). Dumping syndrome can be 
a consequence, if these recommendations are not followed (34). Early dumping occurs within 
1 hour after eating, and is caused by rapid fluid shifts and release of GI hormones into the 
intestinal lumen. The result can be contractions, pain, bloating and diarrhoea (34). Other 
important factors that should be addressed to avoid discomfort during the first period after BS, 
are separation of liquids from solid food, and intake of liquids in small portions. When the 
patient has returned to a solid diet, its highly recommended that simple carbohydrates are 
avoided at best efforts. Patients are encouraged to gradually increase the intake of foods rich in 
dietary fibre (35).  
 
The energy intake is normally decreased short time after BS, followed by an increase at a later 
point of time (33, 36). The post-operative diet generally provides a very low caloric intake (500-
800 kcal/day). This is usually followed the first weeks after surgery (33). Although current 
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evidence is conflicting when it comes to the long-term results of BS, a lot of patients seems to 
stick to a diet with a lower caloric intake post-surgery compared with baseline (37). This is in 
accordance with the fact that BS overall is effective in terms of weight loss (11).  
 
As for the average population, the general dietary advices are highly relevant for BS patients, 
with some adaptations to customize the diet after the specific procedure. It is difficult to give 
individual recommendations for energy intake in general, due to great variations in the degree 
of physical activity, body composition and resting metabolism. An estimation of daily energy 
consumption for an inactive female is 2150 kcal, and 2600 for an inactive male. The Norwegian 
recommendations for intake-distribution of macronutrient energy percentage is 45-60 for 
carbohydrates, 25-40 for fat, and 10-20 for protein (38). By using estimated recommended daily 
nutrient consumption for an inactive man (2600 kcal), one can calculate estimated 
macronutrient recommendations. That gives us that the estimated recommended macronutrient 
intake for a man will approximately be between: 293-390 grams of carbohydrates, 72-116 
grams of fat, and 65-130 grams of protein.   
 
1.3 Colorectal cancer 
CRC is an umbrella term for cancer types that starting in the colon and rectum, and they are 
often grouped together due to many of the overlapping features. Most CRC debuts as growths 
on the inner lining of the colon or rectum, known as polyps (21). The most common type is 
adenocarcinoma, accounting for about 96% of CRC cancers. Carcinoid tumours, GI stromal 
tumours, lymphomas, and sarcomas are other less common types of CRC (21).  
 
CRC is the second most commonly diagnosed cancer form in women, and the third most 
common in men. The risk is higher in the Western parts of the world (Europe, Australia, United 
states, New Zealand), compared to countries in Africa and Asia (39). Diet and lifestyle are 
stated as important factors for the geographical differences (40). During the past decades, CRC 
has become a huge public health problem, and the prevalence of CRC is expected to further 
increase in the following years. Today, CRC risk accounts for approximately 10% of all cancer 
related mortality (41). In addition, the proportion of young adults getting diagnosed with CRC 
are increasing, even though the CRC risk is higher with increased age (42). Indeed, 75% of the 
people with rectal cancer and 80% of the people with colon cancer is older than 60  
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years at the time of diagnosis (41). Off note, about 90% of CRC causes occurs without any 
familiar history or genetic predisposition. 
 
1.3.1 CRC risk, diet and lifestyle 
The risk of having CRC is mainly associated with an unhealthy lifestyle, including increased 
BMI, smoking, low physical activity, low vegetable and fruit consumption and increased red 
meat intake (39, 42). Overall 16 % of new CRC cases have been shown to be preventable if all 
the potentially modifiable healthy lifestyle factors had a minimum impact. This includes, 
healthy weight, physical activity, smoking, alcohol consumption, and diet. The association was 
observed to be stronger among men than among women (43).  
 
The relationship between red meat intake and CRC is well established as the evidence for an 
increased risk of CRC from consuming red and processed meat is strong (44). Several possible 
mechanisms have been suggested for this association, but the exact mechanisms underlying is 
still uncertain (45). Meat intake increases protein fermentation, as well as inducing increased 
intake of fat, heme and heterocyclic amines, which are suggested to play a role in CRC 
development (46).  
 
On the other hand, carbohydrate fermentation is generally accepted as beneficial for the host 
due to the generation of short chain fatty acids (46). Dietary fibre intake has been linked to 
reduced risk of colon cancer (47). There is also strong evidence that intake of wholegrains 
decreases the risk of CRC (48). Suggested mechanisms behind this includes that wholegrains 
have a protective effect by binding carcinogens and regulating glycaemic response (48). 
Specific compounds in wholegrains have also been shown to stimulate anti-oxidative activity 
in experimental studies (48).  
 
1.3.2 Colorectal cancer risk and bariatric surgery 
Obesity is related to an overall increased risk of cancer, and higher amounts of body fat are 
associated with increased risk of a number of specific types of cancers, including CRC (49). 
Several studies are suggesting a decreased risk of obesity related cancers in general after BS (6, 
10, 50, 51).   
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Even though the overall cancer risk seems to be reduced after BS, this is not the case for certain 
specific types of cancer, meaning that the weight reduction following BS might not lead to a 
decrease in all obesity-related cancers. Several studies have concluded with a decreased overall 
cancer risk, but with an elevated risk of CRC after BS (52, 53). The risk is seen to increase over 
time after BS (53, 54).  
 
So far, it can be concluded that the results in studies exploring the change in CRC risk after BS 
are conflicting. While some studies suggest an increase in CRC risk following BS, other studies 
identified a decreased risk for all obesity-related cancers specifically, including CRC in the 
period after BS (10, 55).  
 
Possible mechanisms that link BS to an increased risk of CRC are associated with the metabolic 
changes after surgery. A suggested link between BAs and CRC is the alteration of the intestinal 
epithelium caused by the secondary BAs, which are implicated as colon cancer promotors that 
has shown to be cytotoxic to colonic epithelial cells (56). There are still a lot of unanswered 
questions regarding the pathways involved. One theory is that BAs alter the stability of the 
membrane lipid bilayer, due to their detergent properties. The structure of the membrane is 
more easily damaged by BAs with increased hydrophobicity (57). Additionally, the role of BA-
microbiota crosstalk in GI-cancer has gotten more attention recently. The gut microbiota can 
transform intestinal BAs to their unconjugated forms, which are seen to be more carcinogenic 
(58). In this way, the change in microbiota after BS can affect the CRC risk through interaction 
with the BAs.  
 
1.4 Cytotoxicity 
Cytotoxicity refers to the ability of a certain compound of being toxic to cells (59). When cells 
are exposed to a cytotoxic compound, different responses such as ceased cell growth and/or a 
halt in active division of cells (a decrease in cell proliferation) can occur. In more serious cases, 
the cell can undergo necrosis, apoptosis or autophagy. 
 
Diet related faecal cytotoxicity is correlated with risk of colon cancer (60). This is partly 
through compounds from processed and red meat (45). Lately there has also been more focus 
on protein fermentation and CRC risk. Protein fermentation is considered detrimental for the  
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host’s health (46). The link between protein fermentation and CRC has been emphasized in 
particular due to protein being a major constituent of meat (46). In addition to this, it has been 
observed that protein fermentation becomes more dominant in the distal colon, which is the 
area most affected by disease (61).  
 
In a study conducted on FW cytotoxicity in ulcerous colitis (UC) patients, results showed that 
FW from the UC patients was significantly more cytotoxic than FW from health controls. Here, 
higher FW cytotoxicity was associated with specific protein fermentation metabolites, as well 
as lower levels of medium and short chain fatty acids (62).  
 
Measurement of cytotoxicity can play an important role when studying the potential effects of 
a substrate on human cells. Cytotoxicity can be measured in several different ways. The water-
soluble tetrazolium salt (WST)-1 cell assay is one of the most used methods to measure cell 
viability. The principle is the reduction of the tetrazolium salt WST-1 to the yellow colored 
formazan by cellular dehydrogenases. Formazan production is quantified by measuring UV-
absorption at 120-480 nm which reflects the level of mitochondrial activity. If a cell is dead, no 
such activity will be left. In this way the number of living cells are counted indirectly (59).  
 
With regard to the risk of CRC, faecal content examination is a non-invasive way of studying 
exposures to the colorectal mucosa, which can give us a lot of information. Feces represents 
the bacterial metabolism in the colon (60). Feces is composed of water, protein, undigested fats, 
polysaccharides, bacterial biomass, ash and undigested food residues (63).  
 
As of today, there has only been performed animal studies looking at FW cytotoxicity after BS, 
and knowledge on FW cytotoxicity after BS in human subjects is limited. In a study that 
measured the toxicity in the FW of RYGB-operated rats, the results showed an obvious increase 
in the cytotoxicity of the FW post-surgery. The study included faecal samples from 12 rats at 2 




2. Aim of the study 
2.1 Aim 
This thesis was written as a part of a larger research project, where the overall aim was to study 
the effect of BS on the colonic health and gut environment. The hypothesis was that possible 
changes in the colonic environment after BS can affect colonic health after surgery. These 
changes are thought to be different for RYGB than for SG, as proximally to the colon, distinct 
anatomical changes are induced after these surgery types. Further on, to underpin the overall 
aim of the research project, the objective of this thesis was to evaluate changes in faecal water 
cytotoxicity, diet and stool consistency in patients who underwent bariatric surgery. 
 
2.2 Research questions  
This master project had 4 specific research questions: 
1. How does the FW cytotoxicity change from before BS to one year after? 
2. How does the macronutrient composition change in the BS patients from before surgery 
to one year after surgery? 
3. How is the stool consistency changed in the one year period after surgery? 
4. Can the cytotoxicity analysis protocol (WST-1 assay) be more effective by changing 


















3. Material and methods  
Collection and analysis of the data in this thesis were completed and obtained in the period 
between the 12th of August 2019 and the 13th Of March 2020.   
 
3.1 Study design  
The project was a prospective 1-year follow-up study, including 2 groups of BS patients and 1 
group of obese controls, with a goal to include in total 195 participants, 65 per group. The BS 
patients had prior to surgery their first of in total 5 visits for the study. The other 4 clinical visits 
were planned after 2 weeks, 3 months, 6 months, and 1 year after surgery. The control (CTR) 
group followed the same visit schedule, with baseline (when included), 2 weeks, 3 months, 6 
months and 1 year (Figure 2).  
 
The patient’s visits were, if possible, synchronized with consultations at the doctor/dietician in 
the hospital. All participants received a stool collection kit for each visit (Appendix 2). During 
the patient visit, 4 blood samples of 25 ml were drawn, of which one were immediately placed 
on ice. In addition, a faecal sample, a general health questionnaire, a 7-days dietary record and 
a 7-days stool diary (rating of consistency) were brought to the visit (Appendix 1). Medication 










































= intervention (surgery or group sessions) 
Figure 2: Overview study visits 
 
3.2 Study population 
The study included 3 groups. The BS participants were recruited into 2 groups, one group with 
patients that should undergo RYGB, and one with patients referred to SG. A multidisciplinary 
team consisting of a surgeon, endocrinologist, psychologist and dietician from the obesity clinic 
(UZ Leuven) decided what procedure (SG or RYGB) to perform on individual patients. The 
third group of participants was the CTR group. This group included obese, but otherwise 
healthy participants on a weight loss diet, through a group program at the Obesity clinic of UZ 
Leuven. The program consisted of 15 sessions of behavioural therapy and diet counselling in a 
period of 12 months. The cytotoxicity analysis included 2 groups. One group consisting of 
RYGB and SG patients, and one group consisting of CTR participants. 
Signing of informed 
consent 
• Faecal sample 
• Blood sample 
• 7 day food diary 
• 7 day stool diary 
• Medical record 











The BS surgery participants were recruited at the obesity Clinic of UZ Leuven (Leuven, 
Belgium) by Charlotte Evenepoel (PhD-candidate) in collaboration with Dr. Lannoo and Prof. 
Dr. Van Der Schueren. In addition, BS participants were recruited at a second hospital i.e AZ 
Diest (Diest, Belgium). Here the stool samples were delivered at the lab, and blood samples 
from patients were taken by the clinical biologist at site. This subset participants were also 
operated by DR. Lannoo. The group of obese but otherwise healthy participants were recruited 
at the Obesity Clinic of UZ Leuven on their introduction session, also by Charlotte Evenepoel 
(PhD-candidate). 
 
3.2.2 Inclusion criteria  
For the BS participants, the standard criteria for BS should be fulfilled: BMI40 kg/m2 or 35 
kg/m2 in combination with either obstructive sleep apnoea syndrome, severe high blood 
pressure not treatable with 3 types of medication, or type 2 diabetes. In addition, other 
underlying causes of obesity were to be excluded by an endocrinologist. Furthermore, the 
patient had to have tried loosing weight in a non-surgical way for at least 1 year without positive 
results. People under the age of 18 years were not regarded as suitable for surgery. Additional 
inclusion criteria were no previous major abdominal surgery in the past, and no GI problems. 
During the last month, and the 2 weeks before the study, all participants were required to not 
antibiotics or pre-and probiotics, respectively. For the control group, criteria for inclusion were 




3.2.3 Subgroups for specific analysis  
Different numbers of participants were included in each analysis performed for this thesis. This 
was due to the timeframe of the project, missing values and unpredicted challenges in the 
experiments. The number of included participants is clarified at the beginning of the current 
subchapter in the results for each specific analysis. 
 
3.3 Sample processing  
After the participant’s visits, collected samples and documents were brought back to the 
laboratory at translational research centre for gastrointestinal disorders (TARGID). All samples 
from all participants were labelled with the necessary information: Patient ID, visit, name of   
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study, date, and type of sample. Information about the processing of the blood and stool samples 
for each patient were registered and saved both on paper, and in digital format.  
 
3.3.1 Stool samples 
 
3.3.1.1 Handling of faecal samples  
At each visit, the participants brought a stool sample, collected in a pot, and one divimat with 
a aliquote from the same sample. The divimat is a soft plastic mat for collecting small pellets 
of faeces (Appendix 2) In their stool diary, the participants had to rate their stool consistency 
for 7 days with a score from 1-7 (where 1 equals hard, and 7 is liquid) using the validated Bristol 
Stool Form Scale. 
 
Stool sample pot 
The plastic pot with the faecal sample was stored in the fridge at 4C until processed. Further 
processing had to be done within 7 days after the sample was collected by the participant. Upon 
processing, the faecal sample was distributed into tubes and ultra-centrifuged at 22000 rounds 
per minute (RPM), for 2 hours, at 4C. After the centrifugation, the FW was collected into a 
plastic tube (Sarstedt AG & Co) and vortexed. This was to ensure that the content was 
homogenized. Finally, the FW was aliquoted into the 4*2mL (in some cases less) Eppendorf 
tubes (Sarstedt AG & Co) and placed on -80°C until further analysis. 
 
Faecal dry weight 
Before aliquoting the divimats, Eppendorf tubes (Sarstedt AG & Co) for measuring dry 
substance were weighted when empty. After the participants visit, the divimat was immediately 
stored in a freezer. The frozen pellets were aliquoted separated into 4 different plastic tubes, 
used for different measures. After aliquoting, the filled tubes were again weighted. Further on, 
after freeze-drying, the Eppendorf tubes were weighted for the third, and last time. To calculate 
the amount of dry substance (faecal dry weight) in the stool samples, a lyophilizer (CHRIST) 
was used to freeze-dry the samples. Samples were placed in small hard-plastic cups with 4 filled 
Eppendorf tubes in each cup. All the tubes were opened, and the hard-plastic cup was then 
covered by a cotton pad held in place by a rubber band. Thereafter, samples were frozen before 




Filtering faecal water 
The FW was filtered before performing the cytotoxicity test to remove solid material, bacteria 
and other living microorganisms. Filtration was done through a two-step process; first step 
including using a 0.8l, followed by a 0.2l filter (Sarstedt AG & Co). After defrosting, the 
samples were centrifuged for 5 minutes, at 5000 RPM. In the next step, the FW was poured into 
a new Eppendorf tube (Sarstedt AG & Co) to obtain supernatans and remove the pellet collected 
at the bottom of the tube. Filtering was done by pushing all the FW through the filter by using 
a 10mL syringe (Henke Sass Wolf). One filter of each size, and one syringe per patient sample 
were used. The samples with a higher viscosity gave more resistance when going through the 
filter, thus more time consuming. Some of the samples with the highest viscosity needed to be 
partitioned into 2 filters. After filtering through both filters sizes, FW was stored in at -80C 
until further analysis. 
 
3.4 Cytotoxicity measurement of faecal water 
3.4.1 Cell culture  
Human colonic adenocarcinoma HT-29 cells used were obtained from ECACC (European 
Collection of Cell Cultures), grown in RPMI-1640 medium (ThermoFisher), with fetal bovine 
serum (50mL per RPMI medium flask, (in-house)), and antibiotics (gentamicin sulphate, 250l 
per RPMI medium flask, (Gentauer)), at 37 C and with 5% CO2. Cells were defrosted at 
passage 147. The cells were counted using countess cell counter (Invitrogen). The cells were 
split, and the medium changed twice a week throughout the whole experiment.     
 
3.4.2 WST-1 Assay 
Cytotoxicity of the FW was measured using a WST-1 assay. Before incubating the cells with 
FW, they were loosened from the culture bottle, counted, pipetted into a 96-well plate (104 cells 
per plate) with flat bottom, and kept in the incubator for 24 hours. Afterwards, the cells were 
exposed to serial dilutions (1/4-1/508) of FW samples in fresh medium, and then placed in the 
incubator (37 C, 5% CO2) for 72 hours. At 71 hours of incubation, Trition X-100 was added 
as positive control and medium was used as negative control. At 72 hours, the reaction was 
stopped by splashing the plates as much as needed. Next, 10-mL (per plate), tetrazolium salt 4-
[3-[4-iodophenyl]-2-4-(4-nitrophenyl)-2H-5-tetrazolio-1,3-benzene disulphonate (WST-1) 
dilution (1/10) was added. As WST-1 is light sensitive, the light was switched off when   
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preparing, and adding the dilution to the cells. In addition, the 96-well plates were wrapped in 
aluminium foil before placing back into the incubator (37 C, 5% CO2). The plates were taken 
out for measurement of the absorbance at 2 and 4 hours after adding WST-1 dilution. The 
measurements were done with a spectrophotometer, at 450nm wavelength (2103 Envision 
Multilabel Reader, Perkin Elmer, Waltham, MA). The viability of the negative control was set 
as 100%. The results are expressed as dilution at which 50% of the cells died.  
 
Six different pools of FW were used as test samples. These were all a mix of different samples 
from the entire study population. The two reasons for starting the experiment with only pools 
were 1) To test the protocol without spilling samples, using pools as “dummy samples”, and 2) 
To decide which pool to use in all the sessions with patient samples. In each session with 
participant’s samples, we added minimum one pool as a control sample. This allowed us 
checking the quality of that experiment such that the variability between the samples is mostly 
biological and not due to technical variability. 
 
3.5 Food diaries  
An anonymous MyFitnessPal (MFP) account was created for each participant to fill in the 7-
day dietary record before each visit. A manual of use was provided, to ensure correct reporting. 
MFP is an online, free application where the participants could register everything they drink 
and eat. The data could be extracted automatically by the researcher, to see the macronutrient 
intake per day. The participants could search an extensive database (MyFitnessPal food 
database) for food items, in addition to scanning barcodes. If it for some reason was difficult to 
fill the diary in digitally, it was also an option to note the intake on paper and bring this to the 
visit.  
 
3.6 Data analysis 
 
3.6.1 Stool consistency and percentage faecal dry weight 
The analysis of Bristol Stool Scores (BSS) from the 7 days stool diary were used to determine 
the stool consistency. Faecal DW (dry weight) percentage were used for further evaluations of 
faecal dryness. To calculate the amount of dry substance (in g), first weight of an empty tube 
was subtracted from the filled tube (tube + stool sample). Secondly, the percentage DW was 
calculated from the total weight (both water and DW).  
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3.6.2 Nutrient intake 
After individual participants had registered their dietary intake at MFP, PDFs with their 
estimated daily intake were first extracted from their user accounts. Secondly, the conversion 
program (Zamzar) was used to transform the PDF files to TXT documents. At this stage, all 
the diaries were double checked for errors manually, by a nutrition bachelor student. Thirdly, 
all the files were merged into one Excel file with an in-house script in R language. This script 
contained an additional quality control that removed single nutrient values that went above a 
defined cut-off value. These cut-off values were: 1500 kcal, 95 g carbohydrates, 92 g fat, and 
52 g protein per food item. Finally, the food diaries were sorted by patient and time point.  
 
3.6.3 Cytotoxicity  
Inhibitory concentration (IC)-50 
Results from measurements after 4 hours were used for further analysis. The cell survival was 
calculated as: Survival (%) = (Asample – Apos.control) / (Aneg.control - Apos.control) x 100. 
IC-50 is a ratio that expresses the dilution, and there is no unit used for this. All the FW samples 
were done in triplicate.  
 
3.6.4 Methodological validation: Comparison of duplicate vs. triplicate analysis of 
cytotoxicity 
After preforming the samples in triplicate for the first period of the experiment, there was a 
chance to evaluate if it was possible to make the protocol more efficient for further 
implementation. Specifically, the intention was to explore changes in accuracy of doing the 
samples in duplicate compared to doing it in triplicate. The purpose of doing this was to 
consider doing one extra patient sample per plate,  
  
The first step in comparing the IC-50 results of duplicates vs. triplicates was to split up all the 
results into duplicates as an addition to the already available triplicate values, using the same 
template. At this point we had two sets of IC-50 values ready for statistical comparison. For 
this analysis, a smaller share of the results was removed, compared to the cytotoxicity analysis. 
The reason for this was that even if the final IC-50 were unreliable, the information about the 
difference in the raw data triplicates were useful for this purpose.  




3.7 Ethics  
The study was approved by the Committee for Medical Ethics of UZ KU Leuven (s59836). 
All the participants signed a written consent. The study was carried out according to the 
Declaration of Helsinki, and according to the guidelines for good clinical practise. The 
participants did not receive any compensation for the participation in this study.    
 
3.8 Statistical analysis  
IBM SPSS statistics version 25 was used to perform statistical analysis. Data from the energy 
and macronutrient intake, stool consistency (BSS) and percentage faecal DW were compared 
using a mixed model ANOVA regression analysis. The statistical differences at different time 
points are not included in this thesis. The three different groups (RYGB, SG and CTR) were 
compared to each other. Multiple comparison between the groups were performed using 
Turkey’s honest significant difference post-hoc test. A P-value <0.05 was considered 
statistically significant. A paired t-test was used to compare the two data sets (duplicate IC-50 


















4.1 Faecal water cytotoxicity by WST-1 assay 
Results of FW cytotoxicity measured 4 hours after applying WST solution were included in the 
cytotoxicity analysis. FW cytotoxicity results were included regardless of missing time points, 
because of the limited number of samples. One of the participants had delivered a stool sample 
at 14 months because of missing samples, this was included in this analysis. Energy, 
macronutrient, BSS and percentage DW data from the 9 participants included in cytotoxicity 
analysis were also included in this section. The BS participants (RYGB and SG) were merged 
into one group in this section, and the two groups (BS and CTR) were compared for the 5 
different time points. No statistics were performed for this data. 
 
4.1.1. Sample selection cytotoxicity analysis 
Samples from 9 participants were included in the analysis (Figure 3). These participants were 
the first ones recruited. All samples from 2 participants (the same WST-1 assay session) were 
excluded because the results were defined as unreliable, the living cell numbers in the plate 

























Figure 3: Flow chart sample selection cytotoxicity 
Samples analysed with 
WST  
 n = 11 
 
Unreliable results 
n = 2 
No point of IC-50 
n = 2 
Final samples included 
n = 9 
Bariatric surgery 
n = 5 
Control group 
 n = 4 
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4.1.2 Baseline characteristics of the participants from the faecal water cytotoxicity 
analysis 
Baseline characteristics of the participants included in the FW cytotoxicity analysis are 
presented in Table 1. All missing values can be seen in Appendix 3. The baseline FW 
cytotoxicity levels were higher in the BS group compared with in the CTR group, with a 
difference of 50.9. Faecal DW percentage and BSS were similar in both groups, with a 
difference of 0.08 percentage points for faecal DW and 0.33 points for BSS. The baseline 
energy intake was 146 kcal/day higher in the BS group compared to the CTR group. The 
differences were more distinct in the macronutrient intake, with the CTR group consuming on 
average 19.12 g/day more carbohydrates and 7 g/day more protein than the BS group at 
baseline, whereas the BS group consumed on average 18.5 g/d more fat than the CTR group. 
 
 
 Table 1: Baseline characteristics of participants included in faecal water cytotoxicity analysis 
 
1. Energy, carbohydrates, fat, and protein intake are presented as estimated average daily intake from 
MyFitnessPal registration (4-7 days) 











Variable Bariatric surgery participants 
N=5 
Control group participants 
N=4 
 Mean (min-max) Mean (min-max) 
Age (years) 46.2 (33-69) 50.5 (24-63) 
BMI 35.7 (34.14-37.37) 36.6 (34.6-38.3) 
Cytotoxicity FW (IC-50) 66.87 (6.57-122.54) 15.97 (12.24-19.81) 
Faecal DW (percentage) 26.59 (16.72-30.57) 26.67 (20.19-35.44) 
BSS 3.67 (3-4) 4 (3-5) 
Energy intake (kcal) 1486 (845-2199) 1340 (1257-1716) 
Carbohydrates intake (g) 148.7 (131-845) 167.82 (144-222) 
Fat intake (g) 63.5 (22-107) 45 (44-52) 
Protein intake (g) 54.11 (33-76) 61.1 (48-78) 
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4.1.3 Cytotoxicity level (IC-50) 
FW cytotoxicity level for all participants, at all time-points measured are presented in Figure 
4. The overall trend is higher cytotoxicity values in the surgery groups than in the CTR group. 
Three of the BS group participants also have markedly higher levels compared to the CTR 






BS=Bariatric Surgery group (both RYBG and SG), CTR=Control group 




Figure 4: Overview of cytotoxicity level (IC-50), from baseline to one year after surgery 
 
 
4.1.4 Energy and macronutrient intake  
Energy intake for all visits are presented per group in Figure 5. There was seen a trend of more 
stable energy intake over the 5 visits in the CTR group compared to the BS group. The BS 
group showed a decrease in energy intake between baseline and 2 weeks, before increasing 
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                BS=Bariatric Surgery group (both RYBG and SG), CTR=Control group 
                  Energy intake presented as mean group intake at each visit. 
                  Intake is presented as average kilocalories/day estimated from MyFitnessPal food diaries (4-7 days) 
 
              Figure 5: Overview of energy intake from participants included in  
                               cytotoxicity analysis, from baseline to one year after surgery 
 
 
Macronutrient intake (carbohydrates, fat and protein) for all visits is presented in Figure 6. The 
trend of a more stable intake in the CTR group compared to in the BS group is clearly shown 
here. The difference between the two groups were greater for the carbohydrate intake compared 
to fat and protein. At two weeks after surgery, the difference between the groups were more 
























              BS=Bariatric Surgery group (both Roux-en-Y-gastric-bypass and Sleeve gastrectomy), 
              CTR=Control group, Carb=Carbohydrates 
              T0=baseline, T2W=Two weeks, T3M=Three months, T6M=Six months, T12M=Twelve months 
              Macronutrient intake estimated as mean group intake at each visit.  
              Intake is presented as average grams per day estimated from MyFitnessPal food diaries (4-7 days). 
 
           Figure 6: Overview of macronutrient intake from participants included in  
                           cytotoxicity analysis, from baseline to one year after surgery 
 
4.1.5 Change in cytotoxicity, faecal dry weights, BSS, energy intake and macronutrient 
intake, from baseline to one year after surgery 
Mean values for cytotoxicity, DW, BSS and energy and macronutrient intake from all visits are 
presented in Table 2. Overview of missing values can be found in Appendix 3. The trend 
among participants in the BS group for cytotoxicity seems to be a decrease from baseline and 
to two weeks after surgery. From two weeks, the cytotoxicity increases between each of the 
remaining visits. The difference between baseline and 12 months was 101.02. 
 
For cytotoxicity, there was observed a smaller difference between the visits in the CTR group 
compared to between the visits in the BS group. In the CTR group, there was a decrease between 
baseline and 2 weeks of 2.8. In addition, it was a decrease between 3 and 6 months of 1.24. The 
difference between baseline and 12 months in the CTR group was 9.11.  
 
For faecal DW percentage, there was seen a decrease of 2.8 percentage points between baseline 
and two weeks post-surgery in the BS group. Further on, an increase is seen between two weeks 
and 3 months, before values stabilizes throughout the remaining time of the study. In 























































in the BS group. For the CTR group there was an increase in the faecal DW percentage between 
6 and 12 months of 7.78 percentage points. 
 
In terms of energy and macronutrient data, it was a more distinct difference between the two 
groups compared to for the other variables. It was a decrease in intake of energy, carbohydrates 
and fat between baseline and two weeks post-surgery in the BS group, reflecting a decreased 
intake after the surgery. As expected, this trend was not seen in the CTR group. The general 
intake seems to be relatively stable for all visits in the CTR group, while there were bigger 

























Table 2: Change in cytotoxicity, faecal dry weights, BSS, energy and macronutrient intake, from baseline to one year after surgery 
 
 






















































































































































































 1. Energy, carbohydrates, fat, and protein intake are presented as estimated average daily intake from My fitness Pal registration (4-7 
days) 




4.2 Energy and macronutrient intake  
Energy and macronutrient intake (carbohydrates, fat and proteins) during the follow-up year 
were included in this analysis. The results are including three groups (RYGB, SG and CTR). 
Energy, carbohydrates, fat and protein intake were compared statistically between groups 
across all 5 time points. The change over time for each component is visualised through figures, 
and were not analysed statistically.    
 
4.2.1 Sample selection food diaries for energy and macronutrient intake analysis  
Food diaries from 67 participants were included in energy and macronutrient analysis. The 
selection is presented in Figure 7. The cut off point for removing participants from the analysis 
were set at minimum 4 visits. For removing diaries (one visit) the threshold was set at minimum 
three days, which led to an exclusion of eight diaries, while an additional 20 diaries were 































Food diaries  
n = 77  
Removed because 2 or 
more missing time 
points 
n = 20 
Final included 





4.2.2 Baseline characteristics energy and macronutrients intake analysis 
Baseline characteristics of the participants included in energy and macronutrient intake analysis 
are presented in Table 3. All missing values are specified in Appendix 3. Mean age was similar 
between the groups. Mean BMI was higher in the RYBG and SG groups compared to the CTR 
group. 
 
The mean baseline energy intake was 171 kcal/day higher in the CTR group compared with in 
the SG group. For carbohydrates, the difference between CTR and SG was 2.04 g/day, while 
between CTR and RYGB the difference was 6.04 g/day. A more substantial difference in fat 
intake (13.3 g/day CTR vs. SG) and (7.15g/day CTR vs. RYGB) was detected, compared to 
carbohydrates. Protein showed greater difference for CTR vs. SG (3.93 g/day) compared with 




 Table 3: Baseline characteristics of participants included in energy and macronutrient 
                intake analysis 
1. Energy, carbohydrates, fat, and protein intake are presented as estimated average daily intake from 
MyFitnessPal registration (4-7 days) 














 Mean (min-max) Mean (min-max) Mean (min-max) 
Age (years) 46.36 (26-69) 44.22 (21-64) 47.59 (28-63) 
BMI 39.92 (34.14-49.48) 40.20 (35.01-52.57) 35.79 (29.75-45.17) 
Energy intake 
(kcal) 
1644 (846-2630) 1768 (839-3370) 1597 (943-2347) 
Carbohydrates 
intake (g) 
175.13 (99.43-332.43) 181.19 (85.57-304.33) 179.15 (123.86-302.29) 
Fat intake (g) 66.51 (25.79-107.14) 72.55 (18-154.83) 59.35 (30.33-111.43) 
Protein intake (g) 68.33 (33.50-109.14) 66.09 (4.83-158.83) 70.02 (41.29-122.86) 
 34 
4.2.3 Change in energy and macronutrient intake  
For the multiple comparison between the groups the results for energy, carbohydrates and fat 
were similar. There was a statistical significant difference when comparing the CTR group with 
both surgery groups for energy, carbohydrates and fat, while there was no statistical significant 
difference between the two surgery groups (Table 5-7). The protein intake did not differ 
between any of the groups. (Table 8) 
 
There was a clear difference in trends between the surgery groups and the CTR group (Table 
4). For the surgery groups the energy, carbohydrates and fat intake decreased markedly between 
baseline and two weeks after surgery, before gradually increasing towards the 12 months 
follow-up. The baseline level was higher compared to 12 months for all variables besides 
protein. In the RYGB group, the trend for protein was similar as for other macronutrients. In 
the SG group on the other hand, the protein intake at 12 months was higher than at baseline. 
For the CTR group there was less variation for both energy and macronutrient intake compared 
to the surgery groups. There was a small decrease for all variables between baseline and 12 
months in the CTR group. The change from baseline to 12 months for energy, carbohydrates, 


















        Table 4: Change in energy and macronutrient intake from baseline to one year 































1. Energy, carbohydrates, fat, and protein intake are presented as estimated average daily intake from 
MyFitnessPal registration (4-7 days) 






















































































































































































               Error bars are showing standard error for all time points 
                  CTR=Control, RYBG= Roux-en-Y-gastric-bypass, SG=Sleeve gastrectomy 
 
               Figure 8: Change in energy intake, from baseline to one year after surgery 
 
 
  Table 5: Multiple comparison of energy intake, across all 5 time points  
1. A mixed model ANOVA regression analysis were used 
2. P-value from Turkey’s honest significant difference post-hoc test 
































P-value 95% Confidence Interval 
    
Lower bound Upper bound 
CTR RYGB 483 0.00 241 727 
CTR SG 411 0.02 133 692 
SG RYGB 71 0.76 -170 316 
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               Error bars are showing standard error for all time points 
                  CTR=Control, RYBG= Roux-en-Y-gastric-bypass, SG=Sleeve gastrectomy 
 
               Figure 9: Change in carbohydrate intake, from baseline to one year after surgery  
 
 
Table 6: Multiple comparison of carbohydrate intake, across all 5 time points  
 
1. A mixed model ANOVA regression analysis were used 
2. P-value from Turkey’s honest significant difference post-hoc test 





































P-value 95% Confidence Interval 
    
Lower bound Upper bound 
CTR RYGB 59.62 0.00 33.13 86.12 
CTR SG 57.34 0.00 26.95 87.73 
SG RYGB 2.29 0.98 -24.20 28.78 
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                Error bars are showing standard error for all time points 
                   CTR=Control, RYBG= Roux-en-Y-gastric-bypass, SG=Sleeve gastrectomy 
 




    Table 7: Multiple comparison of fat intake, across all 5 time points 
 
1. A mixed model ANOVA regression analysis were used 
2. P-value from Turkey’s honest significant difference post-hoc test 
































P-value 95% Confidence Interval 
    
Lower bound Upper bound 
CTR RYGB 19.07 0.00 9.93 28.22 
CTR SG 17.41 0.01 6.92 27.90 
SG RYGB 1.66 0.90 -7.48 10.80 
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                  Error bars are showing standard error for all time points 
                  CTR=Control, RYBG= Roux-en-Y-gastric-bypass, SG=Sleeve gastrectomy 
 




       Table 8: Multiple comparison of protein intake, across all 5 time points 
 
1. A mixed model ANOVA regression analysis were used 
2. P-value from Turkey’s honest significant difference post-hoc test 
3. CTR=Control, RYBG= Roux-en-Y-gastric-bypass, SG=Sleeve gastrectomy 
 
 
4.3 Stool consistency (BSS), and faecal dry weight analysis  
Faecal DW percentage and BSS results are presented in this section. Faecal DW percentage 
was obtained from freeze drying a small part of the stool sample delivered at each visit. The 
BSS was filled in for 7 days in the stool diary delivered at each visit. The results are including 
three groups (RYGB, SG and CTR). Faecal DW and BSS were compared statistically 
between groups across all 5 time points. The change over time for each of the 2 components is 



































P-value 95% Confidence Interval 
    
Lower bound Upper bound 
CTR RYGB 9.94 0.33 -6.89 26.76 
CTR SG 2.31 0.96 -16.98 21.61 
SG RYGB 7.63 0.52 -9.20 24.45 
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4.3.1 Sample selection faecal dry weight and Bristol Stool Score analysis 
 
The final number of participants included in faecal DW analysis were 82, as presented in Figure 
12. The cut-off point for selection was set at a minimum of 4 visits data available. As a result 
of this, 35 participants were removed.  
 
Four BSS values were missing among these 82 participants, hence the final number of 
participants included in BSS analysis were 78, as presented in Figure 13. These 78 participants 
were selected from the 82 participants included in faecal DW analysis to be able to compare 
























Figure 12: Flow chart faecal dry weight   Figure 13: Flow chart Bristol Stool Score 
 
 
4.3.2 Baseline characteristics faecal dry weight and Bristol Stool Score  
 
Baseline characteristics of the participants included in faecal dry weight and Bristol Stool Score 
analysis are presented in Table 9 and 10. All missing values are specified in Appendix 3. For 
the participants in faecal dry weight analysis the age difference was greatest between CTR and 
SG (5.38 years) compared with CTR and RYGB (4.6 years). For BMI, the group differences 
for CTR vs. SG showed 3.52 kg/m2, and CTR vs. RYGB showed 3.18 kg/m2. Faecal DW 
Freeze dried faecal samples 
 n = 117  
 Removed because of 3 
or less visits available 
n = 35 
Final included 
n = 82 
 
BSS of the participants 
included in faecal DW 
analysis 
n = 78 
Final included 
n = 78 
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percentage was only differing 1.33 percentage points between the 2 surgery groups. 
Additionally, there was little variation between the groups for baseline levels of BSS, the 















1 The Bristol Stool Form Scale is from 1-7 




 Table 10: Baseline characteristics of participants included in Bristol Stool Score analysis  
 
 
1 The Bristol Stool Form Scale range is from 1-7 




4.3.3 Change in faecal dry weight and BSS from baseline to one year after surgery 
It was no significantly overall group difference for neither faecal dry weight nor BSS (Table 
12 and 13). The change over time differed between the 3 groups, as presented in Table 11. The 
faecal dry weight was for both surgery groups higher at 12 months compared to baseline. The 
change in faecal dry weight by groups over time are shown in Figure 14. 
 
For BSS, the same trend as for faecal dry weight were observed in the RYGB group, except for 
the change between baseline and 2 weeks. Here, both faecal DW and BSS was decreasing. In 







 Mean (min-max) Mean (min-max) Mean (min-max) 
Age (years) 45.43 (26-69) 44.65 (20-61) 50.03 (24-72) 
BMI 39.96 (34.14-52.05) 40.30 (32.6-52.57) 36.78 (29.75-49.08) 
Faecal DW 
(percentage) 






 n=29  
Mean (min-max) Mean (min-max) Mean (min-max) 
Age (years) 46.66 (26-69) 43.86 (20-60) 49.93 (24-77) 
BMI 40.09 (34.14-52.05) 40.33 (32.6-52.57) 36.85 (29.75-49.08) 
BSS 4.26 (3-7) 4.52 (3-7) 4.07 (1-6) 
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two weeks, and between three and 6 months. In terms of the CTR group the trends were also 
opposite for faecal dry weight and BSS between all the different visits. The change in BSS by 
groups over time are shown in Figure 15. 
 
 






















1. The Bristol Stool Form Scale range is from 1-7 




































































































                   Error bars are showing standard error for all time point 
                   CTR=Control, RYBG= Roux-en-Y-gastric-bypass, SG=Sleeve gastrectomy 
 
                Figure 14: Change in faecal dry weight, from baseline to one year after surgery 
 
 
Table 12: Multiple comparison of faecal dry weight, across all 5 time points 
 
1. A mixed model ANOVA regression analysis were used 
2. P-value from Turkey’s honest significant difference post-hoc test 


























% dry weight 
P-value 95% Confidence Interval 
    
Lower bound Upper bound 
CTR RYGB -1.43 0.66 -5.36 2.49 
CTR SG -0.13 0.99 -4.63 4.36 
SG RYGB -1.30 0.75 -5.62 3.02 
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                   Error bars are showing standard error for all time points 
                   CTR=Control, RYBG= Roux-en-Y-gastric-bypass, SG=Sleeve gastrectomy 
 
                Figure 15: Change in Bristol Stool Score, from baseline to one year after surgery 
 
 









1. A mixed model ANOVA regression analysis were used 
2. P-value from Turkey’s honest significant difference post-hoc test 




























P-value 95% Confidence Interval 





CTR RYGB -0.15 0.75 -0.67 -0.36 
CTR SG -0.20 0.70 -0.79 -0.40 
SG RYGB 0.04 0.98 -0.54 0.63 
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4.4 Methodological validation: Comparison of duplicate vs. triplicate 
analysis of cytotoxicity 
The FW cytotoxicity samples included in the methodological validation results are selected 
from the same WST-1 assay analysis as the samples in the FW cytotoxicity results. The samples 
were from RYGB, SG and CTR group participants, separated into to datasets (duplicate and 
triplicate) for statistically comparison.  
 
4.4.1 Sample selection methodological validation: comparison of duplicate vs. triplicate 
analysis of cytotoxicity 
Seventy-seven IC-50 results were included in the methodological validation (Figure 16). To be 
able to do the comparison between duplicate and triplicate the original sample had to be 





























Figure 16: Flow chart IC-50 faecal water in duplicate and triplicate 
 
 
IC-50 results  
n = 84 
 Not done in triplicate 
n = 2 
No point of IC-50 
n = 5 
 
Final analysed 
n = 77   
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4.4.2 Comparison duplicate and triplicate analysis of toxicity 
 
The mean IC-50 value in the duplicate data did not differ significantly from the triplicate data. 













































5. Discussion  
5.1 Main findings  
The main findings corresponding to the 4 main research questions will be discussed in the same 
order as presented in the results. As the study populations are different in the 4 subchapters, the 
results will not be compared directly.  
 
 
5.1.1 Cytotoxicity  
The WST-1 assay results for cytotoxicity showed a trend of more cytotoxic faecal water among 
the BS group compared to the CTR group. However, it is difficult to say if this trend is due to 
the procedure itself, especially since the baseline levels also are higher in the surgery group 
(IC-50: 66.87 in surgery group vs 15.97 in CTR group), or simply due to the low number of 
participants. The lowest level of cytotoxicity in the BS group was found at 2 weeks. This is also 
the visit with the lowest faecal DW and highest BSS (more towards liquid consistency of stool). 
This is interesting due to the assumption of higher amounts of water in the stool contributing to 
diluting possible toxic compounds.  
 
In addition to the general trend of higher cytotoxicity in the BS surgery group, it was a trend of 
increasingly higher levels of cytotoxicity between two weeks and 12 months was detected in 
the same group. Interestingly, this trend was not seen in the CTR group, which provides 
incentive for exploring the reason for differences further. 
 
The visit two weeks after surgery, which had the lowest cytotoxicity level in the BS group, was 
also the visit with the lowest energy intake in the same group. It is naturally to think that the 
energy intake can influence the level of cytotoxicity, because of a smaller amount of possible 
cytotoxic compounds coming through the food intake. Two weeks after intervention had in 
addition the lowest cytotoxicity level in the CTR group, but the decrease compared to the other 
visits was smaller in this group vs the BS group. The caloric intake was not lower at two weeks 
compared to the other visits in the CTR group. Even though it´s not possible to say that this 
proves correlation, based on data attained for this thesis, it unveils a knowledge gap and 
incentive for further research on this subject.     
 
The FW used for cytotoxicity analysis were filtered through 2 different filters. The last one with 
a 0.2µm pore size, which means sterile filtration (65). This gives some extra precautions to 
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prevent contamination in the process. Faeces consists largely of bacteria, which is removed in 
this stage of filtering (63). The possible sources of cytotoxicity were not analysed in this thesis. 
For possible further, and more thorough cytotoxicity research, an analysis of protein 
fermentation metabolites, short chain fatty acids, and secondary BAs could give deeper insight 
in the source of increased cytotoxicity (46, 62, 66).  
 
To this date, no previous publications reporting FW cytotoxicity in BS patients have been 
identified. There has been performed a study on FW cytotoxicity (measured in IC-50 with 
WST-1 assay) in patients with ulcerative colitis (UC) (62). Data were obtained from healthy 
CTRs, UC patients with active disease and UC patients in remission. The results showed 
significantly more cytotoxic FW from the UC patients compared with healthy CTRs. The range 
of IC-50 values in the healthy CTR group were 11.9-22.5 compared with 12.9-34.5 in the UC 
patients. The IC-50 results for the BS group were substantially higher in the study conducted 
for this thesis. The mean values from the different visits varied from 38.82-167.89. The CTR 
group participants from our study varied from 13.17-25.08, which are similar to the results for 
healthy CTRs in the UC study.  
 
Also, an experimental BS study in rats has been performed (64). FW from the RYGB operated 
rats were found to be highly cytotoxic. The results here were similar to the cytotoxicity findings 
in the present study.  
 
Hence, results from the study conducted for this thesis provide new knowledge to this field of 
research. Measures of FW cytotoxicity by WST-1 assays are of note not something commonly 
performed, thus it’s difficult to directly compare values with different references. Off note, it is 
impossible to draw any conclusions from these results due to the limited number of participants. 
 
5.1.2 Energy and macronutrient intake  
We observed a significantly overall difference for energy intake, carbohydrate intake and fat 
intake between the RYGB group participants and the CTR group participants, and between the 
SG group participants and the CTR group participants (Table 5-7). The protein intake was not 
found to differ notably between the groups. It is likely to assume that the differences observed 
between the CTR group and the surgery group is influenced by the dietary restrictions in the 
time after the surgery. This assumption is drawn because the most obvious difference in the 
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intake between the two surgery groups and the CTR group is observed twoo weeks after 
surgery. 
 
Previously performed studies have shown a tendency of weight regain in a long-term 
perspective after BS (11, 67). In addition, there has previously been shown an increase in energy 
intake between one month and 12 months post-surgery (36). These findings are similar to the 
results in the present study and gives premises to longer follow up studies after BS in the future. 
In spite, it’s important to mention that weight is not taken account for in this analysis.   
 
At 12 months, there is a 321-kcal difference for the RYGB group compared with baseline, and 
a 397-kcal difference for the SG group (Table 4). Even though the highest intake amount were 
reported at the baseline visit for both groups, the baseline levels were still low compared to an 
average recommended intake (1644 kcal/day for RYGB, 1767 kcal/day for SG and 1597 
kcal/day for CTR) (38). Off note, the overall calorie intake was low where none of the three 
groups exceeded 1800 kcal/day at any time-point during the 1-year follow-up. The Norwegian 
general dietary recommendations for an inactive man is a daily intake of 2600 kcal, hence the 
average intake in this study is markedly lower (38). The baseline food registration was collected 
without any restriction, and is therefore supposed to represent the participant’s regular diet. 
These are all obese individuals, hence the low registered caloric intake does most likely not be 
a long-term reflection of their diet. Set aside the factors mentioned above, it is important to 
acknowledge the fact that the groups consist of both genders with a wide range of age groups, 
hence the nutritional requirements and recommendations will naturally be of great variety.   
 
The composition of the macronutrients changed differently in the BS groups compared to the 
CTR group between baseline and 12 months. Protein intake was decreasing predominantly 
between baseline and 12 months in the CTR group (5.7 g/day) compared to in the BS groups. 
The protein intake was also decreased in the RYGB group between baseline and 1 months, 
although not as abundantly (2.71 g/day) as in the CTR group. For SG on the other hand, the 
protein intake increased between baseline and 12 months (16.21 g/day). The fat intake 
decreased between baseline and 12 months in all three groups. The smallest decrease was found 
in the CTR group (5.95 g/day), compared to 15.89 g/day in the RYGB group and 23.89 g/day 
in the SG group. In terms of change in diet between baseline and 12 months, observed changes 
in protein and fat intake can give us an indication of a greater shift towards the general dietary 
recommendations in the surgery groups (38). However, this is solely an assumption, due to the 
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lack of information about the different types of carbohydrates and fats consumed by 
participants. Studies have showed BS to be more effective than other weight loss interventions 
(7, 68). Weight loss was not analysed in the present study. Nevertheless, our results were 
showing a greater dietary change in the BS groups compared to in the CTR group. Off note, it’s 
not feasible making any conclusions from results in this thesis due to a short timeframe of which 
this study was performed, and the limited number of participants. 
 
5.1.3 Stool consistency  
There were seen no significant differences in the multiple comparison between groups across 
all time points for neither faecal DW nor BSS. Therefor we cannot conclude with any 
difference in terms of stool consistency after BS. The results from faecal DW showed a higher 
percentage (more towards constipation) one year after surgery, compared with baseline values 
in both BS groups. For the RYGB group the increase was 3.2 percentage points, for SG the 
increase was 5.23 percentage points. In contrast, a smaller difference between baseline and 12 
months in the CTR group were observed (0.35 percentage points).  
 
For BSS, it was hardly any changes between baseline and 12 months in the RYGB group (0.02 
point). The results showed a decrease in BSS (more towards constipation) between baseline 
and 12 months for the SG and CTR group (0.77 and 0.12 point, respectively).  
 
When looking at the results from BSS and faecal DW they are showing the same trend for SG, 
but not for RYGB and CTR. For the two BS groups, the change is more towards a solid 
consistency overall. This can be discussed in context with the fact that a lot off BS patients are 
experiencing constipation as a side-effect after surgery (31). Constipation is defined with a BSS 
of 1 or 2 (69). The results from BSS in this study were showing mean scores for all groups at 
all visits above 3. Even though the results were more towards constipation for the SG group 
and CTR group when comparing baseline and 12 months, there is no evidence to conclude with 
constipation being a problem based on these data. For faecal DW, there has not been determined 
cut-off points for constipation and diarrhoea.    
 
5.1.4 Methodological validation  
When comparing the IC-50 cytotoxicity results in triplicate and duplicate, no significant 
difference between the two methods were observed (p=0.34). Based on the findings in this 
thesis, it seems reasonable to continue future research and similar experiments in duplicate 
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analysis, as this will save both time and recourses. It’s worth noting that the ability to remove 
outlying values is removed when going from triplicate to duplicate. This means that those 
values are automatically included due to the impossible task of determining the most correct 
value 
 
5.2 Strengths and limitations  
5.2.1 Participants 
The main limitation regarding the participants, is the fact that the four-different main analysis, 
targeting the four different research questions does not include the same number of participants. 
This makes it difficult to compare the examined variables with each other. Regardless of this, 
all the included participants had similar characteristics, due to fact that they were all obese and 
can give us useful information about a population group that is prioritised too little. This can 
facilitate important direction pointers towards where future research where future research in 
this group should be initiated. 
 
Due to the timeframe and methodological adversity, the main focus of the thesis (cytotoxicity) 
had a very low number of included participants. This leads to the fact that the results were not 
suitable for statistical analysis. This is naturally a limitation. The fact that the participants 
selected for analysis were included by inclusion number, and not by other considerations is also 
a limitation. There were missing FW samples because of missing visits, drop out, or due to the 
amount of faecal sample, which is a limiting factor to the follow up results.  
 
The number of participants included in energy and macronutrient analysis were a lot higher 
than in cytotoxicity analysis, and the increased number of participants is a strength. This gives 
more credibility to the observed trends in addition to the fact that this made it possible to 
perform statistics on the obtained results. Another limitation is the unequal division of 
participants between the groups (30 / 20 / 17), considering the fact that groups are compared. 
The rate of inclusion of participants from the different groups are impossible to control, which 
is reflected in the unequally numbered groups. The decision to rather include more participants 
than to have a lower, but equal number, was made to strengthen the results.  
 
Eighty four participants were included in faecal DW analysis and 78 were included in the BSS 
analysis, which is a higher number of participants than for other analyses performed in this 
study. The number of participants is a strengthening factor. Here, the cut-off point for exclusion 
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were one missing time point, which led to 35 participants being excluded. It is a strength to 
avoid too many missing time points when the aim is to observe change by time after surgery.  
 
For the methodological validation, the number of participants are also limited for the same 
reasons as for the cytotoxicity analysis. Regardless, the fact that each of the samples were done 
in triplicate, which was tested in this analysis, provides a higher number of samples.    
 
5.2.2 Analysis  
 
Cytotoxicity 
There are a number of steps in processing and preparing the faecal sample for cytotoxicity 
analysis. The main limitation is the representability of the faecal sample collected. The faecal 
sample was mostly collected from one day, in some cases two days if the amount was 
insufficient, especially in cases of constipation. Even though the BSS and frequency are 
registered for one week before each visit, there is only one stool sample collected for each visit. 
Only speculations can be made about how much the recent food and drink intake, physical 
activity etc. influence the cytotoxicity result on a short term. This is off note beyond the scope 
of this thesis, but absolutely something worth looking further into. Stool consistency can 
possibly affect the measurement of cytotoxicity, which is not considered in the results. The 
explanation behind this, is the fact that a high amount of water in the FW will dilute the other 
possible cytotoxic compounds in the sample. The steps of homogenizing are crucial in the 
process of obtaining FW before filtering. If this is not done properly, the final tubes of FW will 
only be representable for parts of the delivered stool sample.  
 
The WST-1 assay is a commonly used, practical and safe measure of cytotoxicity. Regardless 
there are many critical steps in the protocol where things can go wrong and affect the results. 
The cells/cell counter used in this project was to some degree a limiting factor. From the very 
beginning of the experiment, a challenge arose in attempting to obtain the correct number of 
cells in the wells used. This was discovered through a low number of living cells in the wells 
only filled with medium. There was also used a second cell counter to double check the counted 
number of cells, where number of counted cells seemed to vary too much between the different 
culture bottles of cells used. 
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The main reason for obtaining the low number of results in the cytotoxicity analysis were a 
contamination in the cell culture used. When this was discovered the experiment was paused 
further on.  
 
Energy and macronutrient intake 
There are several limitations both regarding the way the data is collected, and for the choice of 
data collection resources. Firstly, the data is registered by the participants themselves. This 
leads to uncertainties, as it is impossible to control in any way if the registration is representative 
of the participant’s intake. The risk of over and under estimating is a known challenge when 
recording food intake (70).   
  
There are additional limitations of the application MyFitnessPal. Some food items are missing 
in the database. Although there is a function to register new food items with the full nutritional 
content, it can be a challenge to register information correctly, as well as it requires a lot of 
extra work for the participants. For some participants, the digital registration can be difficult. 
An attempt to avoid the digital format from being a hinder was to offer the possibility to register 
on paper. Even though the digital format can be a source of wrongly estimation of intake for 
some participants, the value of having an app always available on your phone exceeds this 
aspect. The chance of misunderstanding the use off the application is also limited from having 
a detailed guide of how to correctly register nutrient intake. 
 
Stool consistency 
The results can give us an idea of the uncertainty of using both BSS and faecal DW, since the 
two measures are giving slightly varying results. Additionally, it’s challenging to compare the 
results because the BSS was representing one week (stool diary), while the faecal DW was only 
from one single stool sample. There is seemingly no way of correctly converting faecal DWs 
to BSS, since BSS is strictly based on appearance. Faecal DW percentage and BSS as a measure 
of stool consistency both have some limitations. The amount of DW left after extracting the 
water from the stool sample is an indirect measurement of the consistency, that says something 
about how dry a sample is.  
 
There will always be a possibility for mistakes that may influence the results in most research. 
This includes both mistakes related to the machines and equipment used, and to the methods 
proceeded by hand. For the faecal DW, the weighing procedure is crucial, where  the final 
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results are unreliable if incorrect weight is registered at any of the numerous steps. Even though 
the mistakes most likely would be noticed, there is always a risk linked to this kind of analysis. 
The BSS is a well-known method of stating the stool consistency. This method is based on 
categorization, and has been shown to be reliable (71). Regardless, there will always be a risk 
of different interpretations between the participants rating the stool samples.  
 
Methodological validation  
Because of the relatively low number of samples included in the methodological validation 
analysis (77), there is a higher chance of the results being incidental. There will be a variation 
in pipetting mistakes over time. This results are regardless of this, useful to have in mind for 























6. Conclusion and future aspects   
In conclusions, we detected a trend of higher cytotoxicity in BS patients compared to healthy 
obese controls according to the cytotoxicity analysis, and the cytotoxicity gradually increased 
between 2 weeks and 12 months after surgery. The energy and macronutrient analysis 
highlighted a observed difference in the overall energy, fat and carbohydrate intake between 
both RYGB and CTR, and SG and CTR. The same difference was not seen for the protein 
intake. Further, we observed a decrease in intake of energy and macronutrients between 
baseline and 2 weeks after surgery, before a gradual increase towards 12 months in the BS 
groups. The same trend was not observed for the control group.  
 
The need of studies further investigating the implications of faecal cytotoxicity in BS patients 
is clear, as there is little existing research. The increasing prevalence of both obesity and CRC 
makes this highly relevant, especially because the prevalence’s are increasing in the younger 
population. A longer and more detailed analysis of the cytotoxicity after BS can give a better 
picture of the mechanisms involved in CRC development in these patients. Additional detailed 
analysis of the dietary compounds, possibly contributing to these effects, would be of specific 
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Appendix 1: Study documents  
 
Appendix 2: Instructions of how to deliver the stool samples 
 

































































Moest u nog vragen hebben, aarzel zeker niet mij te contacteren.  
 




















Translationeel Onderzoek van Gastro-enterologische Aandoeningen (TARGID) 
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Appendix 3: Tables with number of participants for all variables 
 
 






Age (years) n=5 n=4 
BMI n=5 n=4 
Cytotoxicity FW (IC-50) n=5 n=4 
Faecal DW (percentage) n=5 n=4 
BSS n=3 n=4 
Energy intake (kcal) n=4 n=3 
Carbohydrates intake (g) n=4 n=3 
Fat intake (g) n=4 n=3 
Protein intake (g) n=4 n=3 
1. Energy, carbohydrates, fat, and protein intake are presented as estimated average daily intake from My 
fitness Pal registration (4-7 days) 






















Table 2: Change in cytotoxicity, faecal dry weights, BSS, energy and macronutrient intake, from baseline to one year after surgery 
 





















n=5 n=3 n=3 n=3 n=4 
 
n=4 n=4 n=4 n=4 n=3 
Faecal DW 
(percentage) 
n=5 n=3 n=5 n=4 n=5 
 
n=4 n=4 n=4 n=4 n=4 
BSS n=3 n=3 n=2 n=4 n=4  n=4 n=4 n=4 n=4 n=4 
Energy 
intake (kcal) 
n=4 n=3 n=3 n=4 n=4 
 
n=3 n=3 n=4 n=4 n=4 
Carbohydrat
es intake (g) 
n=4 n=3 n=3 n=4 n=4 
 
n=3 n=3 n=4 n=4 n=4 
Fat intake 
(g) 
n=4 n=3 n=3 n=4 n=4 
 
n=3 n=2 n=4 n=4 n=4 
Protein 
intake (g) 
n=4 n=3 n=3 n=4 n=4 
 
n=3 n=3 n=4 n=4 n=4 
1. Energy, carbohydrates, fat, and protein intake are presented as estimated average daily intake from My fitness Pal registration (4-7 days) 








Table 3: Baseline characteristics of participants included in macronutrient  









1. Energy, carbohydrates, fat, and protein intake are presented as estimated average daily intake from My 
fitness Pal registration (4-7 days) 
2. BMI=Body mass index 
 






1 The Bristol stool scale range is from 1-7 
2 BMI=Body mass index, DW= Dry weight 
 






1 The Bristol stool scale range is from 1-7 








Variable RYGB SG CTR 
Age (years) n=30 n=19 n=17 
BMI n=30 n=20 n=17 
Energy intake (kcal) n=30 n=19 n=17 
Carbohydrates 
intake (g) 
n=30 n=19 n=17 
Fat intake (g) n=30 n=19 n=17 
Protein intake (g) n=30 n=19 n=17 
Variable RYGB SG CTR 
Age (years) n=30 n=17 n=31 
BMI n=32 n=19 n=30 
Faecal DW 
(percentage) 
n=32 n=19 n=31 
Variable RYGB SG CTR 
Age (years) n=29 n=16 n=29 
BMI n=31 n=18 n=29 
BSS n=31 n=18 n=29 
